All In Biotech

Drug Trial Radar · NCT07939815

A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986548 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

171

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Dec 29, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, efficacy, and drug levels of BMS-986548 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies.

Conditions

  • Advanced Solid Malignancies

Interventions

  • BMS-986548Drug

    Specified dose on specified days

  • CetuximabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 30 days after last dose
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to 30 days after last dose
  3. Number of participants with AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteriaTime frame: Up to 30 days after last dose
  4. Number of participants with AEs leading to discontinuationTime frame: Up to 30 days after last dose
  5. Number of deathsTime frame: Up to 30 days after last dose

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Local Institution - 0001

    San Antonio, Texas

  • Local Institution - 0004

    West Valley City, Utah

  • Local Institution - 0002

    Vancouver, British Columbia, Canada

  • Local Institution - 0003

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.